Recent Company News

• 05:02 PM ET Oct 11, 2026
  

  Mirum Pharmaceuticals to host investor call tomorrow, 12-Oct-26 at 08:30ET to share topline results from Phase 3 EXPAND study evaluating LIVMARLI ($86.01, 0.00)

• 02:15 PM ET Oct 09, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 11-Oct

• 01:07 AM ET Sep 30, 2026
  

  Takeda announces new data from three phase 3 LATITUDE psoriasis studies of TAK-279 for psoriasis (¥5782.0000, +43)

• 08:03 AM ET Sep 29, 2026
  

  Keros Therapeutics to receive additional development milestone payment from partner Takeda ($11.28, 0.00)

• 04:54 PM ET Sep 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:03 PM ET Sep 27, 2026
  

  Innovent Biologics expands global Phase 3 MarsLight-11 trial (HK$99.70, 0.00)

• 04:00 PM ET Sep 23, 2026
  

  FDA approves sBLA for Adzynma, officially adding boxed warning to label (¥5968.0000, 0)

• 05:00 AM ET Sep 23, 2026
  

  Innovent Biologics to present clinical data from registrational phase 3 clinical trial of IBI343/TAK-921 at 2026 ESMO (HK$103.40, 0.00)

• 09:52 AM ET Sep 22, 2026
  

  Takeda Pharmaceutical to present phase III TAK-921 gastric cancer data, TAK-928 NSCLC findings at ESMO 2026 (¥5968.0000, 0)

• 11:34 PM ET Sep 17, 2026
  

  Dr. Reddy's Laboratories enters into exclusive distribution and marketing agreement with Takeda regarding Qdenga in India (INR 1172.05, 0.00)